In February 2014, Dilafor entered into licensing and partnership agreement with Lee´s Pharmaceuticals. According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan.

http://dilafor.com/upl/files/136614/dilafor-enters-into-a-license-and-partnership-agreement-with-lee-s-pharmaceutical.pdf


In August 2014, Dilafor entered into a commercial manufacturing and partnership agreement with Opocrin S.p.A for the manufacturing of the active ingredient tafoxiparin. Opocrin is appointed as the main commercial manufacturing partner for Dilafor’s candidate drug for the European, US, CIS and Japanese markets.

http://dilafor.com/upl/files/136609/pr-opocrin-dilafor-final-2014-10-07.pdf

Up to 50 % of all term pregnant women are planned for start of labor with conventional treatments, which carries a high risk of complications for both mothers and infants.